Chronic spontaneous urticaria (CSU) affects approximately 270,000 adults and adolescents aged 12 and older in the European Union, manifesting as unpredictable outbreaks of debilitating hives and intense itch that disrupt daily life. For many, standard first-line treatments like H1 antihistamines provide insufficient relief, leaving patients in cycles of discomfort and frustration. In a landmark development, Sanofi and Regeneron Pharmaceuticals have secured European Commission approval for Dupixent (dupilumab), marking the first targeted biologic therapy for moderate-to-severe CSU in over a decade.
Muscle-invasive bladder cancer (MIBC) represents approximately 30% of the ~614,000 annual global bladder cancer cases, ranking it as the ninth most common malignancy worldwide. While neoadjuvant cisplatin-based chemotherapy followed by cystectomy remains the standard for eligible patients, up to half of those with MIBC are ineligible for cisplatin due to comorbidities, renal impairment, or other factors, leaving them with limited perioperative options and high recurrence rates—nearly 50% even post-surgery. On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved a transformative regimen: PADCEV® (enfortumab vedotin-ejfv), a Nectin-4-directed antibody-drug conjugate (ADC), in combination with Keytruda® (pembrolizumab) or Keytruda QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), for neoadjuvant treatment followed by adjuvant therapy post-cystectomy in cisplatin-ineligible adults with MIBC.
Neurofibromatosis type 1 (NF1) is a genetic disorder affecting approximately 1 in 3,000 individuals, characterized by the development of benign tumors, including plexiform neurofibromas (PN)—complex, infiltrative growths that often cause significant morbidity such as pain, disfigurement, functional impairment, and reduced quality of life. In adults, symptomatic, inoperable PN represent a particularly challenging subset, as surgical resection is frequently infeasible due to tumor encasement of vital structures, invasiveness, or vascularity, leaving limited therapeutic options.
On November 4, 2025, Application Therapeutics Inc., a precision medicine company specializing in rare genetic disorders, announced the U.S. Food and Drug Administration (FDA) approval of KYGEVVI® (doxecitine and doxribtimine oral suspension), marking a paradigm shift in the treatment landscape for thymidine kinase 2 deficiency (TK2d). This ultra-rare mitochondrial disease, caused by biallelic mutations in the TK2 gene, impairs mitochondrial DNA synthesis, leading to severe skeletal muscle myopathy, respiratory insufficiency, and often early mortality. Affecting approximately 200-300 patients in the U.S., TK2d has historically lacked disease-modifying therapies, leaving families reliant on supportive care amid relentless progression.
On October 28, 2025, Eli Lilly and Company announced U.S. FDA approval for OMVOH™ (mirikizumab-mrkz) as the first and only single 500 mg subcutaneous (SC) injection every 4 weeks for maintenance treatment in adults with moderately to severely active ulcerative colitis (UC) who achieved clinical response to OMVOH induction therapy. This update builds on the drug’s October 2023 approval for both induction (300 mg IV at Weeks 0, 4, 8) and maintenance (200 mg SC every 4 weeks), offering a more convenient, higher-dose option to sustain remission longer-term.
On October 27, 2025, the U.S. FDA approved an expanded indication for WINREVAIR™ (sotatercept-csrk), Merck’s first-in-class activin signaling inhibitor, for adults with pulmonary arterial hypertension (PAH, WHO Group 1). The update incorporates data from the Phase 3 ZENITH trial and now includes reduction in the risk of clinical worsening events—specifically all-cause death, lung transplantation, and PAH-related hospitalization of ≥24 hours—alongside previously established benefits in exercise capacity and WHO functional class (FC).
